Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report

Alsifri, Saud; Elbadawi, Hussein; Alsabaan, Fahad; Almahfouz, Abdulraouf; Al-Yahya, Khalid; Shesha, Eman; Esba, Laila Abu; Alnais, Meshal; Aldahash, Raed; Alharbi, T.J.; Aljaser, Saleh; Issak, Emad R.

doi:10.4236/ijcm.2022.131002

Search citation statements

Order By: Relevance

Paper Sections

Select...

Persons On Daily Injectable Glp1ra1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the manufacturers do not provide equivalent doses of different GLP-1RAs, these have been proposed previously by other experts [ 6 ]. People on a higher dose of these injectables can be directly transitioned to 7 mg oral semaglutide [ 7 ].…”

Section: Persons On Daily Injectable Glp1ramentioning

confidence: 99%

Oral Semaglutide: Dosage in Special Situations

Kalra

Kapoor

2022

Diabetes Ther

View full text Add to dashboard Cite

Glucagon-like peptide 1 receptor agonists (GLP1RAs) have recently gained momentum after the introduction of semaglutide, the first oral molecule in their class. In a recent article in this journal by Evans et al., a succinct overview of the utility of semaglutide is highlighted in the context of virtual diabetes care. To take this discussion further, this commentary describes the value and positioning of oral semaglutide in common clinical situations. Its insights assist in pragmatic placement of this drug in clinical practice. Special emphasis is laid on the use of oral semaglutide in persons already on injectable GLP-1RA formulations, those experiencing sudden changes in life style pattern due to religious, social, or professional commitments, individuals seeking help for urgent glycemic control, and those who face sudden change in their concomitant medications or comorbidities.

show abstract

Section: Persons On Daily Injectable Glp1ramentioning

confidence: 99%